Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...

Addressing the question of whether and how immune cells (macrophages) in the central nervous system (CNS) traffic out, ...

There were still 32,000 new cases of HIV in the U.S. in 2022. And about thousands of people still die annually from AIDS. HIV ...

Leaders in HIV research highlighted the critical role of that research has played in advancing HIV science over the past 40 years. In a commentary in Nature Medicine, they explained how U.S.-funded ...

The "miracle tool" HIV medicine lenacapavir will be sold in South Africa from as early as March or April 2026 according to ...

By Aneri Pattani for KFF Health News. Broadcast version by Kathryn Carley for Maine News Service reporting for the KFF Health ...

The world may look back on 2024 as a pivotal time in the fight against AIDS — the start of a revolution in the global biomedical response to HIV using long-acting antiretroviral medicines. Young women ...

The American South has the highest HIV rates in the country, accounting for more than half of new HIV diagnoses nationwide in 2023. This is despite growing availability of a highly effective HIV ...

The US Department of State has announced a life-saving development to bring US-based Gilead Sciences’ breakthrough drug lenacapavir to market in Uganda, one of just ten high-burden HIV/Aids countries ...

The NIH funding will help address a "traditional barrier" to health care, says Elizabeth Evans, professor of community health ...

Through a US$ 29 million grant, South Africa will receive enough medicine to provide HIV prevention to 450 000 people at high ...